Published: November 13, 2019

Introduction {#sec1}
============

*Prevotella* is classically considered a common commensal bacterium due to its presence in several locations of the healthy human body, including the oral cavity, gastrointestinal tract, urogenital tract, and skin ([@bib42]). The *Prevotella* genus encompasses more than 40 different culturable species of which three---*P. copri* (*Pc*), *P. salivae* (*Ps*), and *P. stercorea*---are members of the gut microbiota. *Prevotella* has been reported to be associated with opportunistic infections, e.g., periodontitis or bacterial vaginosis ([@bib42]). Moreover, *Prevotella* is the major genus of one of the three reported human enterotypes ([@bib7]), but how *Prevotella* behaves in different gut ecosystems and how it interacts with other bacteria of the microbiota and/or with its host is not well defined. In addition, high levels of genomic diversity within *Prevotella* strains of the same species have been observed ([@bib19], [@bib32]), which adds another layer of complexity for predicting the effects of *Prevotella* strains. Recent studies have linked higher intestinal abundance of *Pc* to rheumatoid arthritis ([@bib1], [@bib48], [@bib65]), metabolic syndrome ([@bib57]), low-grade systemic inflammation ([@bib57]), and inflammation in the context of human immunodeficiency virus (HIV) infection ([@bib23], [@bib40], [@bib47]), suggesting that some *Prevotella* strains may trigger and/or worsen inflammatory diseases ([@bib42], [@bib45], [@bib58]).

The microbiota plays a central role in protecting the host from pathogens, in part through colonization resistance ([@bib13]). In the case of *Listeria monocytogenes* (*Lm*), the foodborne pathogen responsible for listeriosis, the intestinal microbiota provides protection, as germfree mice are more susceptible to infection than conventional mice ([@bib5], [@bib10]). Treatment with probiotics such as *Lactobacillus paracasei* CNCM I-3689 or *L. casei* BL23 was shown to decrease *Lm* systemic dissemination in orally inoculated mice ([@bib4]). Unravelling the interactions between the host, the microbiota, and pathogenic bacteria is critical for the design of new therapeutic strategies via manipulation of the microbiota. However, identifying specific molecules and mechanisms used by commensals to elicit their beneficial action is challenging due to the high complexity of the microbiome, together with technical issues in culturing many commensal species. In addition, cooperative interactions between commensal species are likely to be central to the functioning of the gut microbiota ([@bib61]). So far, mechanism or molecules underlying the impact of commensals on the host or on the infection have been elucidated only for a few species. For example, (i) segmented filamentous bacteria were shown to coordinate maturation of T cell responses toward Th17 cell induction ([@bib27], [@bib36]), (ii) glycosphingolipids produced by the common intestinal symbiont *Bacteroides fragilis* have been found to regulate homeostasis of host intestinal natural killer T cells ([@bib2]), (iii) a polysaccharide A also produced by *B. fragilis* induces and expands Il-10 producing CD4+ T cells ([@bib51], [@bib52], [@bib63]), (iv) the microbial anti-inflammatory molecule secreted by *Faecalibacterium prausnitzii* impairs the nuclear-factor-κB pathway ([@bib60]), (v) *Mucispirillum schaedleri* protects mice from *Salmonella*-induced colitis ([@bib33]), and (vi) *Blautia producta* restores resistance against vancomycin-resistant enterococci ([@bib41]).

Conversely, enteric pathogens evolved various means to outcompete other species in the intestine and access nutritional and spatial niches, leading to successful infection and transmission. In this regard, the contribution of bacteriocins and type VI secretion system effectors during pathogen colonization of the gut is an emerging field of investigation ([@bib9], [@bib62]). Here, we studied the impact of a previous unknown *Lm* bacteriocin (Lmo2776) on infection, and we discovered that *Pc*, an abundant gut commensal, is the primary target of Lmo2776 in both the mouse and human microbiota and as a modulator of infection.

Results {#sec2}
=======

Lmo2776 Limits *Lm* Intestinal Colonization and Virulence in a Microbiota-Dependent Manner {#sec2.1}
------------------------------------------------------------------------------------------

A recent reannotation of the genome of the *Lm* strain EGD-e revealed that the *lmo2776* gene, absent in the non-pathogenic *L. innocua* species ([Figure S1](#mmc1){ref-type="supplementary-material"}A), potentially encodes a secreted bacteriocin of 107 amino acids ([@bib22], [@bib31]), homologous to the lactococcin 972 (Lcn972) secreted by *Lactococcus lactis* ([@bib49]) and to putative bacteriocins of pathogenic bacteria *Streptococcus iniae* ([@bib46]), *Streptococcus pneumoniae*, and *Staphylococcus aureus* ([Figure S1](#mmc1){ref-type="supplementary-material"}B). This gene belongs to a locus containing two other genes, *lmo2774* and *lmo2775,* encoding potential immunity and transport systems ([@bib31]). It is present in lineage I strains responsible for the majority of *Lm* clinical cases ([@bib50]) and in some lineage II strains, such as EGD-e ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Little is known about this bacteriocin family, and studies have focused on Lcn972. Lmo2776 shares between 38% an d 47% overall amino acid sequence similarity with members of the Lcn972 family. Because expression of *lmo2774*, *lmo2775*, and *lmo2776* is significantly higher in stationary phase compared to exponential phase of EGD-e at 37°C in BHI ([Figure S1](#mmc1){ref-type="supplementary-material"}D), all experiments described below were conducted with *Lm* grown up to stationary phase.

We first examined the effect of Lmo2776 on infection. We inoculated conventional BALB/c mice with either the WT, the Δ*lmo2776*, or the Lmo2776 complemented strains and compared *Lm* loads in the intestinal lumen and deeper organs (spleen and liver). We had verified that deletion of *lmo2776* was not affecting expression of surrounding genes, *lmo2774*, *lmo2775*, and *lmo2777* ([Figure S1](#mmc1){ref-type="supplementary-material"}E) or bacterial growth *in vitro* ([Figure S1](#mmc1){ref-type="supplementary-material"}F). Inoculation of mice with Δ*lmo2776* strain resulted in significantly higher *Lm* loads in the small intestinal lumen 24 h post-inoculation (pi) compared to the WT strain ([Figure 1](#fig1){ref-type="fig"}A). These differences persisted at 48 and 72 h pi ([Figure S1](#mmc1){ref-type="supplementary-material"}G). *Lm* loads of Δ*lmo2776* were also significantly higher in the spleen and liver at 72 h pi compared to both WT and Lmo2776-complemented strains ([Figures 1](#fig1){ref-type="fig"}B and 1C). Similar results were observed in C57BL/6J mice (data not shown). Together, these results indicate a key role for Lmo2776 in bacterial colonization of intestine and deeper organs. Following intravenous inoculation of BALB/c mice with WT or Δ*lmo2776* bacteria, bacterial loads at 72 h pi were similar in the spleen and liver ([Figure S1](#mmc1){ref-type="supplementary-material"}H), revealing that Lmo2776 exerts its primary role during the intestinal phase of infection and not later.Figure 1Lmo2776 Limits *Lm* Virulence in a Microbiota-Dependent Manner(A--C) BALB/c mice were inoculated orally with *Lm* WT, Δ*lmo2776*, or Lmo2776 complemented (*p2776*) bacteria. CFUs in the intestinal luminal content (A), spleen (B), and liver (C) were assessed at 72 h pi.(D--F) Germfree C57BL/6J were inoculated with *Lm* WT or Δ*lmo2776* for 72 h and CFUs in the intestinal luminal content (D), spleen (E), and liver (F) were assessed. Each dot represents the value for one mouse. Statistically significant differences were evaluated by the Mann--Whitney test (^∗^p \< 0.05; NS, not significant).

Considering that *lmo2776* is predicted to encode a bacteriocin and that it significantly affects the intestinal phase of infection, we hypothesized that Lmo2776 might target intestinal bacteria, thereby impacting *Lm* infection. To address the role of intestinal microbiota in infection, we orally inoculated germfree mice with WT or Δ*lmo2776* strains and compared bacterial counts 72 h pi. Strikingly, no significant difference was observed between WT and Δ*lmo2776* strains in the small intestinal content ([Figure 1](#fig1){ref-type="fig"}D) nor in spleen and liver ([Figures 1](#fig1){ref-type="fig"}E and 1F). These results showed that the Lmo2776 bacteriocin limits the presence in the deeper organs of WT *Lm* in a microbiota-dependent manner.

Lmo2776 Targets *Prevotella* in Mouse and Human Microbiota {#sec2.2}
----------------------------------------------------------

To identify which intestinal bacteria were targeted by Lmo2776, we compared microbiota compositions of conventional mice orally infected with WT or Δ*lmo2776* strains by 16S rRNA gene sequencing. We first verified that the fecal microbiota composition of all mice was indistinguishable at day 0 ([Figure 2](#fig2){ref-type="fig"}A). As expected, the microbiota composition at day 1 pi was dramatically altered by infection with *Lm* WT ([Figure S2](#mmc1){ref-type="supplementary-material"}A). These alterations in microbiota composition included reduced levels of *Bacteroidetes* phylum (relative abundance before infection: 65.4% and at day 1 pi: 42.4%) and increased levels of *Firmicutes* (relative abundance before infection: 29.9% and at day 1 pi: 54.0%) ([Figure S2](#mmc1){ref-type="supplementary-material"}B--S2E). The increased levels in the *Firmicutes* were mainly due to an increase of the *Clostridia* class (relative abundance before infection: 27.4% and at day 1 pi: 50.7%). Of note, the relative abundance of *Lm* was around 0.1% and cannot therefore explain by itself the increased levels of *Firmicutes* observed between day 0 and day 1. Importantly, at 24 h and 48 h pi, intestinal microbial compositions differed in mice orally inoculated with Δ*lmo2776* strain compared to WT strain ([Figure 2](#fig2){ref-type="fig"}A). We focused on operational taxonomic units (OTUs) for which the relative abundance was identical before infection with *Lm* strains (day −3 to day 0) and was subsequently altered by at least a 2-fold difference at day 1 pi in mice infected with Δ*lmo2776* compared to mice infected with WT strain. In independent experiments, the relative abundance of 12 OTUs was lower in mice infected with WT strain compared to Δ*lmo2776* mutant ([Figures 2](#fig2){ref-type="fig"}B and 2C) at day 1 and also at day 2 pi. Phylogenetic analyses revealed that all these 12 OTUs belong to the *Prevotella* cluster ([Figure 2](#fig2){ref-type="fig"}D). A decrease of *Prevotella* in mice infected with WT strain at day 1 and day 2 pi compared to mice infected with Δ*lmo2776* strain was also observed by qPCR analysis using primers specific for *Prevotella* ([Figure 2](#fig2){ref-type="fig"}E).Figure 2Lmo2776 Targets *Prevotella* in Mouse Microbiota(A) Principal coordinates analysis of the weighted Unifrac distance matrix of mice infected with WT strain or Δ*lmo2776* at days 0, 1, and 2. Permanova: day 0, p = 0.383; day 1, p = 0.05864; and day 2, p = 0.360.(B) Relative abundance of 12 OTUs in gut microbiota of mice inoculated with WT or Δ*lmo2776* strains overtime. Each dot represents the value for one mouse.(C) Heat-map analysis of the relative abundance of 12 OTUs in gut microbiota of mice inoculated with WT or Δ*lmo2776* strains. Each raw represents one mouse. The red and blue shades indicate high and low abundance.(D) Phylogenetic tree of 16S rRNA gene alignment of 5 representative bacteria for each phylum of the bacteria domain, together with OTUs showing significantly different relative abundances in gut microbiota of mice infected with WT or Δ*lmo2776* strains at day 1 (in red).(E) PCR quantification of *Prevotella* in feces of mice inoculated with WT strain or Δ*lmo2776* at day 0 and day 1.

Important differences exist between mouse and human gut microbiota composition. *Prevotella* abundance is known to be low in mouse intestinal content (\< 1%), although it can reach 80% in human gut microbiota ([@bib34], [@bib55]). As *Lm* is a human pathogen, we searched to investigate the impact of Lmo2776 on human gut microbiota. For this purpose, we used a dynamic *in vitro* gut model (mucosal-simulator of human intestinal microbial ecosystem \[M-SHIME\]), which allows stable maintenance of human microbiota *in vitro* in absence of host cells but in presence of mucin-covered beads ([@bib17], [@bib29], [@bib70], [@bib69]) and therefore allows studies on human microbiota independently of the host responses (such as inflammation). The microbiota of a healthy human volunteer was inoculated to the system which was then infected with WT or Δ*lmo2776 Lm*. 16S sequencing to luminal and mucosal M-SHIME samples indicated that before *Lm* inoculation, the bacterial composition in all vessels was similar ([Figure 3](#fig3){ref-type="fig"}A and data not shown). In contrast, following *Lm* addition, luminal microbial community compositions were different in vessels containing WT *Lm* compared to both non-infected vessels and vessels infected with the Δ*lmo2776* isogenic mutant ([Figure 3](#fig3){ref-type="fig"}A). No difference was observed in mucosal microbial community composition. The relative abundance of 7 OTUs was lower in the case of the WT strain compared to the non-inoculated condition or upon addition of the Δ*lmo2776* strain ([Figure 3](#fig3){ref-type="fig"}B). These 7 OTUs all belonged to *Pc* species ([Figure 3](#fig3){ref-type="fig"}C), revealing that Lmo2776 targets *Pc* in human microbiota in a host-independent manner.Figure 3Lmo2776 Targets *Pc* in Human Microbiota and *In Vitro*(A) Relative abundance of genera in SHIME vessels non-infected or infected with WT or Δ*lmo2776* strains. The four more abundant genera are indicated.(B) Relative abundance of 7 different OTUs in SHIME vessels infected with WT or Δ*lmo2776* strains or non-infected. Each dot represents the value for one vessel.(C) Phylogenetic tree of 16S rRNA gene alignment of several *Prevotella* species, together with OTUs showing significantly different relative abundances in vessels inoculated with WT or Δ*lmo2776* strains at day 1 (in red).(D) Levels of propionate in SHIME vessels infected with WT or Δ*lmo2776* strains or non-infected overtime. Results are expressed as mean ± SEM for 2 to 3 individual vessels.(E) Numbers of *Pc* after incubation with supernatant of WT or Δ*lmo2776* strains.(F) Relative abundance of *Pc* and *Bt* after 24 h incubation with increasing dose of Lmo2776 peptide (3 (+), 6 (++) and 9(+++) μg/mL) relative to their abundance without Lmo2776 peptide.(G) Relative abundance of different bacteria after 24 h incubation with Lmo2776 peptide (3μg/mL) relative to their abundance without Lmo2776 peptide. Results are expressed as mean ± SEM of a least 3 independent experiments and P values were obtained using two-tailed unpaired Student's t test (^∗^p \< 0.05, ^∗∗∗^p \< 0.005).(H) PCR quantification of *Prevotella* and *Am* in the feces of mice treated with Lmo2776 peptide (1 mg) or with water relative to their levels before treatment. Each dot represents the value for one mouse. Statistically significant differences were evaluated by Student's t test (^∗∗^p \< 0.01).

As short-chain fatty acid (SCFA) levels serve as a classical readout for gut microbiota metabolism and as *Prevotellae* are known to produce propionate ([@bib26]), we quantified SCFAs production in the luminal M-SHIME samples. A specific decrease in propionate production upon infection with WT *Lm* was observed as early as 6 h pi ([Figure 3](#fig3){ref-type="fig"}D) compared to non-infected and Δ*lmo2776*-infected vessels. This difference was continuously observed up to 3 days pi, while no significant difference was observed for butyrate, isobutyrate, acetate and isovalerate ([Figure S3](#mmc1){ref-type="supplementary-material"}). Although propionate is produced by many bacterial species, the decrease in propionate production observed upon inoculation of M-SHIME with WT *Lm* is in agreement with the decrease in *Pc* population.

Lmo2776 Targets *Pc In Vitro* {#sec2.3}
-----------------------------

We first addressed the direct inhibitory activity of Lmo2776 on *Pc* by growing *Pc* (DSMZ 18205 strain) at 37°C in anaerobic conditions in the presence of culture supernatants of *Lm* strains and counting the viable CFUs on agar plates. Growth of *Pc* dramatically decreased in the presence of the WT *Lm* supernatant compared to the Δ*lmo2776* supernatant or medium alone ([Figure 3](#fig3){ref-type="fig"}E), suggesting that Lmo2776 is secreted and targets directly *Pc*.

To definitively assess the function of Lmo2776, a peptide of 63 aa (Gly69 to Lys131) corresponding to the putative mature form of Lmo2776 was synthesized. Its activity was first analyzed on *Pc* and *B. thetaiotaomicron* (*Bt*), another prominent commensal bacterium ([Figure 3](#fig3){ref-type="fig"}F). A dose-dependent effect of Lmo2776 peptide was observed on *Pc* growth, while no effect was observed on *Bt* growth, demonstrating that Lmo2776 targets *Pc* and not *Bt*. We then tested the effect of the peptide on several other intestinal bacteria, either aerobic (*Enterococcus faecalis*, *Escherichia coli*) or anaerobic (*Akkermansia muciniphila* \[*Am*\]) bacteria. No effect was observed on any of these bacteria ([Figure 3](#fig3){ref-type="fig"}G). Moreover, Lmo2776 peptide did not inhibit growth of seven other *Prevotella* species (*Ps*, *P. oris*, *P. nigrescens*, *P. pallens*, *P. corporis*, *P. melaninogenica*, and *P. bivia*). We next tested the peptide activity on 7 *Pc* isolated from healthy humans and patients. Strikingly, 6 out of the 7 strains were sensitive to the bacteriocin ([Figure 3](#fig3){ref-type="fig"}G).

We also tested the effect of the Lmo2776 peptide on known targets of the bacteriocins of the Lcn972 family (*Bacillus subtilis* \[*Bs*\] and *L. lactis* MG1614). Growth of *Bs* decreased significantly in presence of the peptide ([Figure 3](#fig3){ref-type="fig"}G), while no effect was observed on *L. lactis* growth. Growth of *Bs* was also significantly reduced in the presence of WT *Lm* and of Lmo2776 complemented strains compared to the Δ*lmo2776* strain ([Figures S3](#mmc1){ref-type="supplementary-material"}E and S3F). Addition of the culture supernatant of WT *Lm* to *Bs* significantly decreased the number of *Bs* compared to the addition of Δ*lmo2776* culture supernatant ([Figure S3](#mmc1){ref-type="supplementary-material"}G) ([@bib46]). Together, these results indicate that Lmo2776 is a bona fide bacteriocin that targets both *Pc* and *Bs in vitro.*

To evaluate the effect of Lmo2776 peptide *in vivo*, we used an approach previously described to bypass degradation by enzymes of the upper digestive tract. Conventional BALB/c mice were inoculated intra-rectally with Lmo2776 peptide (1mg per mice, a dose probably higher than the one produced by *Lm* upon infection) or water, taken as a control. Levels of total bacteria, *Prevotella* and *Am* were determined by qPCR on feces collected between 1 and 4 h pi. While no effect was observed on the levels of total bacteria or *Am*, fecal levels of *Prevotella* decreased following administration of Lmo2776 peptide, showing that similar to bacteria, Lmo2776 alone was effective in reducing *Pc in vivo* ([Figure 3](#fig3){ref-type="fig"}H).

Colonization of Germfree Mice by *Pc* Phenocopies the Effect of the Microbiota on *Lm* Intestinal Growth in Conventional Mice {#sec2.4}
-----------------------------------------------------------------------------------------------------------------------------

To decipher the role of *Pc* during *Lm* infection *in vivo*, germfree C57BL/6J mice were orally inoculated with either *Pc* (DSMZ 18205 strain), *Bt* or *Ps,* another *Prevotella* present in the gut, or stably colonized with a consortium of 12 bacterial species (termed Oligo-Mouse-Microbiota (Oligo-MM^12^), representing members of the major bacterial phyla in murine gut ([@bib12])). Two weeks after colonization, mice were orally inoculated with WT *Lm* or Δ*lmo2776* strains and *Lm* loads in the intestinal lumen and target organs were compared 72 h pi. Compared to WT strain, Δ*lmo2776* mutant strain displayed significantly higher loads in the intestinal lumen ([Figure 4](#fig4){ref-type="fig"}A), spleen ([Figure 4](#fig4){ref-type="fig"}B) and liver ([Figure S4](#mmc1){ref-type="supplementary-material"}) in mice colonized with *Pc*, while no difference between the two strains was observed in mice precolonized with *Bt*, *Ps* or the OligoMM^12^ consortium. In addition, the number of *Pc* significantly decreased in WT inoculated *Pc*-colonized animals compared to Δ*lmo2776*-inoculated animals ([Figure 4](#fig4){ref-type="fig"}C). Altogether, these results indicate that the greater ability of the Δ*lmo2776* mutant to grow in intestine and reach deeper tissues compared to the WT strain correlates with the presence of *Prevotella* in the microbiota, as it is observed in either conventional mice or mice colonized with *Pc*. We cannot exclude that the production of the bacteriocin against *Prevotella in vivo* and at 3 days pi has a fitness cost for *Lm* strains.Figure 4*Pc* Controls *Lm* Infection by Modifying Mucus Layer and Promoting Inflammation(A and B) Assessment of listerial CFUs in the intestinal luminal content (A) and in the spleen (B) of germfree (GF) C57BL/6J mice colonized or not with *Pc, Ps* or *Bt* or stably colonized with 12 bacterial species (Oligo-MM^12^) for 2 weeks and then inoculated with *Lm* WT or Δ*lmo2776* for 72 h.(C) Numbers of *Pc* CFUs in the intestinal luminal content of GF C57BL/6J mice colonized with *Pc* and then inoculated with *Lm* WT or Δ*lmo2776* for 72 h.(D) Confocal microscopy analysis of microbiota localization in colon of BALB/c mice infected with *Lm* WT or Δ*lmo2776* bacteria for 24 or 48 h. Muc2 (green), actin (purple), bacteria (red), and DNA (blue). Bar = 20 μm. White arrows highlight the 3 closest bacteria. Pictures are representatives of 5 biological replicates.(E) Distances of closest bacteria to colonic intestinal epithelial cells per condition over 5 high-powered fields per mouse, with each dot representing a measurement.(F) Confocal microscopy analysis of microbiota localization in colon of GF C57BL/6J mice colonized with *Pc*, *Bt* or *Ps* for 2 weeks and inoculated with *Lm* WT or Δ*lmo2776* bacteria. Muc2 (green), actin (purple), bacteria (red), and DNA (blue). Bar: 20 μm.(G) Distances of closest bacteria to intestinal cells per condition over 5 high-powered fields per mouse, with each dot representing a measurement.(H) Levels of the inflammatory marker Lcn-2 in feces of mice 2 weeks pi with *Pc* or *Bt.*(I) Model depicting the effect of *Prevotella* on *Lm* infection. In (A), (B), and (E), each dot represents one mouse. Statistically significant differences were evaluated by the Mann--Whitney test (A, B), one way-ANOVA test (E, G) or two-tailed unpaired Student's t test (C, H) (^∗^p \< 0.05, ^∗∗∗^p \< 0.005).

*Pc* Modifies the Mucus Layer {#sec2.5}
-----------------------------

The intestinal mucus layer forms a physical barrier of about 30μm that is able to keep bacteria at a distance from the epithelium ([@bib38]). A mucus-eroding microbiota promotes greater epithelial access ([@bib21]). *Prevotella*, through production of sulfatases that induce mucus degradation ([@bib71]), might impair the mucosal barrier function and therefore contribute to better accessibility to intestinal epithelial cells and to local inflammation. We thus compared the colonic mucus layer thickness of conventional mice infected with WT *Lm* or Δ*lmo2776* by confocal microscopy, using mucus-preserving Carnoy fixation and FISH ([@bib37]). The average distance of bacteria from colonic epithelial cells was significantly smaller in mice infected with Δ*lmo2776* compared to mice infected with WT *Lm* at 24 and 48 h ([Figures 4](#fig4){ref-type="fig"}D and 4E), suggesting that *Prevotella* present in the microbiota of mice infected with Δ*lmo2776* decreases the mucus layer thickness and might consequently increase its permeability. Of note, these distances were also smaller than in uninfected mice, indicating that *Lm* infection itself affects the mucus layer thickness. To confirm the effect of *Pc* on mucus layer in the context of listerial infection, germfree C57BL/6J mice were precolonized with *Pc* (DSMZ 18205 strain), *Bt*, or *Ps*, then orally inoculated with WT *Lm* or Δ*lmo2776* strains; and mucus layer thickness was analyzed by FISH. In mice precolonized with *Pc*, the average distance of bacteria from colonic epithelial cells was significantly smaller in Δ*lmo2776-*infected mice compared to WT *Lm*-infected mice ([Figures 4](#fig4){ref-type="fig"}F and 4G). Strikingly, such a difference was not observed in germfree mice or in mice precolonized with *Ps* or *Bt*, revealing that mucus erosion is dependent on *Pc*.

Since the thinner mucus layer induced by *Prevotella* could favor invasion of the host by bacteria and contribute to intestinal inflammation, we quantified faecal lipocalin-2 (LCN-2) as a marker of intestinal inflammation ([@bib15]). LCN-2 is a small secreted innate immune protein that is critical for iron homeostasis and whose levels increase during inflammation. Faecal LCN-2 levels were analyzed after colonization of germfree mice with *Pc* compared to non-colonized mice or mice colonized with *Bt*. A significant increase of faecal LCN-2 was observed in germfree mice monocolonized with *Pc* compared to non-colonized animals or to animals monocolonized with *Bt* ([Figure 4](#fig4){ref-type="fig"}H), revealing that *Pc* induces intestinal inflammation. Altogether, these results showed that presence of *Prevotella* in the intestine is associated with a thinner mucus layer and increased levels of faecal LCN-2. They are consistent with previous reports describing *Prevotella* as a bacterium promoting a pro-inflammatory phenotype ([@bib24], [@bib42], [@bib65]).

Discussion {#sec3}
==========

Outcompeting intestinal microbiota stands among the challenging issues for enteropathogens. Pathogens may secrete diffusible molecules such as bacteriocins or T6SS effectors to target commensals and consequently promote colonization and virulence. In most cases, molecular mechanisms underlying the interplay between pathogenic and commensal bacteria in the intestine remain elusive. We previously reported that most strains responsible for human infections, such as the F2365 strain, secrete a bacteriocin that promotes intestinal colonization by *Lm* ([@bib59]). When overexpressed in mouse gut, this bacteriocin, named Listeriolysin S (LLS), decreases *Allobaculum* and *Alloprevotella* genera known to produce butyrate or acetate, two SCFAs reported to inhibit transcription of virulence factors or growth of *Lm* ([@bib56], [@bib68]). However, whether physiological concentrations of LLS have a direct or an indirect role on these *genera* is still under investigation and is a question particularly difficult to address as LLS is highly post-translationally modified and therefore difficult to purify or to synthetize. In the case of *Salmonella enterica* serovar Typhimurium infection, killing of intestinal *Klebsiella oxytoca via* its T6SS is essential for *S. enterica* gut colonization of gnotobiotic mice colonized by *K. oxytoca* ([@bib64]), but whether *K. oxytoca* and other members of the gut microbiota are targeted by the *Salmonella* T6SS in conventional mice is unknown. *Shigella sonnei* uses a T6SS to outcompete *E. coli in vivo* but the effectors responsible for this effect are unknown ([@bib3]).

Here, we report and provide evidence that the Lmo2776 *Lm* bacteriocin targets *Prevotella* in mouse and in *in vitro* reconstituted human microbiota. This effect is direct and specific to *Pc*, as (*i*) *Pc* are killed by *Lm* culture supernatant and by the purified Lmo2776 *in vitro* and (*ii*) despite the complexity of the microbiota and its well-controlled equilibrium, no other genus of the intestinal microbiota was found to be impacted by Lmo2776. By studying Lmo2776, we have unveiled a so-far-unknown role for intestinal *Pc* in exacerbating bacterial infection. The intestinal microbiota, in some cases, has already been reported to promote bacterial virulence by producing metabolites that enhance pathogens virulence gene expression and colonization in the gut ([@bib9], [@bib62]). For example, *Bt* enhances *Clostridium rodentium* colonization by producing succinate ([@bib18], [@bib25]), and *Am* exacerbates *S. Typhimurium*-induced intestinal inflammation by disturbing host mucus homeostasis ([@bib28]). *Pc* decreases the mucus layer thickness and increases propionate concentration and levels of fecal LCN-2, in agreement with previous studies reporting that *Pc* exacerbates inflammation ([@bib24], [@bib65]). In addition, *Prevotella* enrichment within the lung microbiome of HIV-infected patients has been observed and is associated with Th17 inflammation ([@bib66]). *Prevotella* sp. have also been associated with bacterial vaginosis, and their role in its pathogenesis has been linked to the production of sialidase, an enzyme involved in mucin degradation and increased levels of pro-inflammatory cytokines ([@bib11], [@bib67]). Together, our data strongly suggest that *Pc*, by modifying mucus layer permeability and changing the gut inflammatory condition, promotes greater epithelial access and therefore infection by *Lm* ([Figure 4](#fig4){ref-type="fig"}I). We can speculate that individuals with a high abundance of intestinal *Prevotella* might be more susceptible to enteric infections. Interestingly, it was recently shown that subjects with higher relative abundance of *Pc* could be at higher risk to traveler's diarrhea and to the carriage of multidrug-resistant *Enterobacteriaceae* ([@bib44]). In addition, as Lmo2776 bacteriocin allows a selective depletion of *Pc* in the gut, it could prevent excessive inflammation and allow *Lm* persistence and long-lasting infection, eventually leading to meningitis. Further work is required to determine why *Lm* strains have kept the *lmo2776* gene. We showed here that the Lmo2776 bacteriocin also targets *Bs*, a Gram-positive bacterium found in the soil, suggesting that Lmo2776 could give an advantage to *Lm* in that environment. It is possible that Lmo2776 is critical for species survival and replication in a so far unknown niche, consequently favoring transmission or dissemination. *Bs* is also found in the human gastrointestinal tract ([@bib35]) and could be targeted by Lmo2776 in the intestine as well. *Bs* is also targeted by Sil, another member of the Lcn972 family ([@bib46]). The role of the homologs of Lcn972 in other human pathogenic bacteria such as *S. pneumoniae* and *S. aureus* remains to be determined, but conservation of the bacteriocin in different pathogenic bacteria associated with mucosa strongly suggests an important role.

Taken together, our data reveal that *Pc* can modulate intestinal infection, and using Lmo2776 might represent an effective therapeutic tool for *Prevotella*-related diseases to reduce *Pc* abundance in the gut without affecting the remaining commensal microbiota.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Mucin-2 primary antibodySanta Cruz Biotechnologyrabbit H-300**Bacterial and Virus Strains**EGD-e *Listeria monocytogenes* WT strain[@bib72]BUG 1600EGD-e Δ*lmo2776*\
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Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Further information and requests for resources and reagents, including strains and plasmids generated in this study, should be directed to and will be fulfilled by the Lead Contact, Pascale Cossart (<pascale.cossart@pasteur.fr>). All reagents generated in this study are available from the Lead Contact.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Bacterial Strains and Plasmids {#sec4.3.1}

Strains, plasmids and primers used in this study are listed in in the [Key Resources Table](#sec4.1){ref-type="sec"}. For standard experiments, *Listeria*, *E. coli*, *Bs* and *L. lactis* were grown at 37°C with shaking in Brain Heart Infusion (BHI) medium (Difco) and Luria-Bertani (LB) medium (BD). If needed, *Lm* were selected on Oxford medium (Oxoid). Anaerobic bacteria were grown in appropriate medium (PYG medium modified or Schaedler medium or BHI supplemented with 8mM L-Cysteine hydrochloride, 0.2% NaHCO~3~ and 0.025% Hemin, following ATCC or DSMZ recommendations) at 37°C under anaerobic conditions (Genbag Anaer, Biomérieux or AnaeroGen, ThermoScientific). The Lmo2776 deletion mutant was constructed using the pMAD shuttle plasmid ([@bib6]) as described previously ([@bib53]) and confirmed by DNA sequencing. For the construction of pAD-based plasmid, fragment obtained by PCR with EGD-e genomic DNA as template, was cloned into the SmaI/SalI sites of the pAD vector ([@bib8]) derived previously from the pPL2 vector ([@bib43]). Plasmid was verified by sequencing with primers pPL2-Rv and pPL2-Fw and were transformed into Δ*lmo2776* by electroporation. Integration in the chromosome was verified by PCR using primers NC16 and PL95 ([@bib8]). *Pc* strains (AP1411, AQ1172, AQ1173, P54, K2152, T214 and A624) were isolated from stool from healthy subjects and new onset rheumatoid arthritis patients. Stool was collected into anaerobic transport media (Anaerobe Systems), then streaked on BRU and LKV plates (Anaerobe Systems). After 24-48 h, individual colonies were picked and screened with *Prevotella*-specific PCR primers, and the 16S rRNA V3-V4 sequence was confirmed by Sanger sequencing (Fehlner-Peach et al., manuscript in preparation). *Prevotella*-positive isolates were grown on BRU plates, and glycerol stocks were frozen at −80°C.

### Mice {#sec4.3.2}

9- to 12-week-old female BALB/c conventional (Charles River) or C57BL6/J conventional (Charles River) or C57BL6/J germfree (CDTA or Pasteur) or C57BL6/J stably colonized with a consortium of 12 bacterial species (termed Oligo-Mouse-Microbiota (Oligo-MM^12^), representing members of the major bacterial phyla in the murine gut: *Bacteroidetes* (*Bacteroides caecimuris* and *Muribaculum intestinale*), *Proteobacteria* (*Turicimonas muris*), *Verrucomicrobia* (*Am*), *Actinobacteria* (*Bifidobacterium longum subsp. Animalis*) and *Firmicutes* (*Enterococcus faecalis, Lactobacillus reuteri, Blautia coccoides, Flavonifractor plautii, Clostridium clostridioforme, Acutalibacter muris* and *Clostridium innocuum*) ([@bib12])) mice were used for experiments. Germfree and Oligo-MM^12^ mice were housed in plastic gnotobiotic isolators.

All animal experiments were carried out in strict accordance with the French national and European laws and conformed to the Council Directive on the approximation of laws, regulations, and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes (86/609/Eec). Experiments that relied on laboratory animals were performed in strict accordance with the Institut Pasteur's regulations for animal care and use protocol, which was approved by the Animal Experiment Committee of the Institut Pasteur (approval no. 03-49).

Method Details {#sec4.4}
--------------

### Mice Infection {#sec4.4.1}

*Lm* overnight cultures were diluted in BHI and bacteria were grown to an optical density at 600 nm (OD600) of 1. Bacterial cultures were centrifuged at 3,500 × g for 15 min and washed three times in phosphate-buffered saline (PBS). Mice were infected orally with 5 × 10^9^ bacteria diluted in 200 μl of PBS supplemented with 300 μl of CaCO~3~ (50 mg/mL). Serial dilutions of the inoculum were plated to control the number of bacteria inoculated. The different inoculum were closed to 5 × 10^9^ bacteria and the mean ± SEM of all independent experiments were: for WT: 5.03 × 10^9^ ± 0.26 × 10^9^, for Δ*lmo2776*: 5.01 × 10^9^ ± 0.14 × 10^9^ (p = 0.45) or Lmo2776 complemented strain: 4.87 × 10^9^ ± 0.30 × 10^9^ (p = 0.25). Mice were killed at subsequent time points, and intestines, spleens, and livers were removed. The small intestine was opened, and the luminal content was recovered in a 1.5-mL tube and weighed. The small intestine (duodenum, jejunum, and ileum) tissue was washed four times in DMEM (ThermoFisher), incubated for 2 h in DMEM supplemented with 40 μg/mL gentamycin, and finally washed four times in DMEM. All of the organs and the intestinal luminal content were homogenized, serially diluted, and plated onto BHI plates or Oxford plates and grown overnight at 37°C for 48--72 h. CFU were enumerated to assess bacterial load. At least three independent experiments were carried out with four or five mice per group in each experiment. Statistically significant differences were evaluated by the Mann--Whitney test, and differences were considered statistically significant when P values were \< 0.05.

For mice colonization, *Pc*, *Ps* and *Bt* were grown to log phase under anaerobic conditions in PYG modified or Schaedler broth media and 10^7^ CFU were used to inoculate germ-free mice. Feces were collected at 2 weeks post-gavage to confirm colonization. Feces were homogenized, serially diluted and plated on PYG modified, Schaedler or Columbia agar plates.

Six- to 8-week-old female BALB/c mice (Charles River, Inc., France) were injected intravenously with 5.10^3^ CFU of the indicated strain. Mice were sacrificed at 72 h after infection, and livers and spleens were removed. Organs were homogenized and serially diluted. Dilutions were plated onto BHI plates and grown during 24 h at 37°C. Colonies were counted to assess bacterial load per organ.

### Fecal Microbiota Analysis by 16S rRNA Gene Sequencing Using Illumina Technology {#sec4.4.2}

Before infection, 8 BALB/c conventional mice were co-housed for 5 weeks in order to stabilize and homogenize their microbiota. After oral infection, animals were single-housed. Feces were collected and frozen at −20°C. 16S rRNA gene amplification and sequencing were done using the Illumina MiSeq technology following the protocol of Earth Microbiome Project with their modifications to the MOBIO PowerSoil DNA Isolation Kit procedure for extracting DNA ([@bib14], [@bib30]). Bulk DNA were extracted from frozen extruded feces using a PowerSoil DNA Isolation kit (MoBio Laboratories) with mechanical disruption (bead-beating). The 16S rRNA genes, region V4, were PCR amplified from each sample as described in Chassaing et al., 2015 ([@bib16]). Four independent PCRs were performed for each sample, combined, purified with Ampure magnetic purification beads (Agencourt), and products were visualized by gel electrophoresis. Products were then quantified (BIOTEK Fluorescence Spectrophotometer) using Quant-iT PicoGreen dsDNA assay. A master DNA pool was generated from the purified products in equimolar ratios. The pooled products were quantified using Quant-iT PicoGreen dsDNA assay and then sequenced using an Illumina MiSeq sequencer (paired-end reads, 2 × 250 bp) at Cornell University (Ithaca, USA).

### Bacterial Quantification in Feces {#sec4.4.3}

Bulk DNA were extracted from frozen extruded feces using a PowerSoil DNA Isolation kit (MoBio Laboratories) with mechanical disruption (bead-beating). q-PCR reactions were prepared with SYBR Green master mix. Reaction cycling and quantification was carried out in an C1000 touch Thermal cycler (CFX384, Biorad). Genomic DNA from *Prevotella* was used to generate a standard curve to quantitate pg of *Prevotella* present per mg of total feces.

### M-SHIME {#sec4.4.4}

M-SHIME system is a dynamic *in vitro* model which simulates the lumen-associated and mucus-associated human intestinal microbial ecosystem (ProDigest, Ghent University, Belgium) ([@bib29], [@bib70], [@bib69]). It consists of consecutive pH-controlled, stirred, airtight, double-jacketed glass vessels kept at 37°C and under anaerobic conditions. The system was operated as described earlier ([@bib17]) with minor modifications The set-up used here consisted of 3 stomach-small intestine vessels and 9 proximal colon vessels in parallel (3 for non-infected condition, 3 for infection with WT and 3 for infection with Δ*lmo2776*). The colon vessels were inoculated at the start with 40 mL fresh human faecal suspension, from a healthy volunteer with high levels of *Prevotella*, in 500 mL sterile nutritional medium. Every 2 days, half of the mucin agar-covered microcosms were replaced by fresh sterile ones under a flow of N~2~ to prevent disruption of anaerobic conditions. Fourteen days after inoculation, 3 colon vessels were infected with 10^6^ WT bacteria, 3 colon vessels with 10^6^ Δ*lmo2776* and 3 were left uninfected. Lumen (10 ml) and mucin agar samples were taken at 6, 24, 48 and 72 h. Mucin agar-covered microcosms were washed with sterile PBS to remove lumen bacteria. Mucin agar was removed from microcosms, homogenized and stored immediately at −20°C until further analysis.

For 16S rRNA Gene Sequencing, DNA was extracted from 1 mL of lumen samples or 250 mg of mucin agar samples using a PowerSoil DNA Isolation kit and 16S rRNA gene sequencing was analyzed as decribed above.

Our full 16S rRNA gene sequence data are deposited under Study ID PRJEB34638 in the European Nucleotide Archive database (<https://www.ebi.ac.uk/ena>).

For SCFA analysis, lumen samples were diluted 1:2 in demineralized water. Acetate, propionate, butyrate, isobutyrate and isovalerate were extracted and quantified as described ([@bib20]).

### RNA Extraction and qRT-PCR {#sec4.4.5}

A total of 25 mL cultures of bacteria, grown in BHI, was pelleted for 20 min at 3000 g. Pellets were resuspended in 1 mL TRI Reagent (Sigma), transferred to 2 mL Lysing Matrix tubes (MP Biomedicals) and mechanically lysed by bead beating in a FastPrep apparatus (twice 45 s, speed 6.5). Tubes were then centrifuged for 5 min at 8000 g at 4°C to separate beads from lysates. The lysates were drawn off and transferred to a 2 mL Eppendorf tube. 200 uL chloroform was added to the lysate, shaken and incubated 10 min at room temperature, followed by centrifugation for 15 min at 13 000 g at 4°C. The aqueous phase was transferred to a new tube and RNA was precipitated by the addition of 500 uL isopropanol and incubation at room temperature for 10 min. RNA was pelleted by centrifuging for 10 min at 13000 g at 4°C, washed twice with 75% ethanol. RNA pellets were resuspended in 50 to 100 uL water. For each sample, 10 ug of RNA was treated with Dnase (Turbo DNA-free, Ambion) following manufacturer's instructions. cDNA was synthetiszed from 1 ug of RNA using QuantiTect Reverse Transcription (QIAGEN) and reactions were subsenquently diluted with 180 ul of water. qRT-PCR reactions were prepared with SYBR Green master mix. Reaction cycling and quantification was carried out in an C1000 touch Thermal cycler (CFX384, Biorad). Expression levels were normalized to the *rpoB* gene. Samples were evaluated in triplicate and results represent at least three independent experiments.

### Co-cultures and Culture in Presence of Supernatant or Lmo2776 Peptide {#sec4.4.6}

For co-culture assays with *Bs*, a mixture of equivalent CFU (10^7^) of *Bs* and *Lm* (WT, Δ*lmo2776* or p2776) was inoculated into 5 mL of fresh BHI and incubated at 37°C for 6 h. Serial dilutions were plated on BHI and on Oxford media for CFU enumeration.

For culture of target in presence of *Listeria* supernatant, 25 mL of overnight culture of *Listeria* were centrifuged at 13000 g and the supernatants were collected and centrifuged further to remove cells and cells debris. Supernatants were filtered through a 0.20μm pore size filter (Millipore). 10^7^ bacterial targets (*Bs*, *E. coli* or *Pc*) were inoculated at 37°C into 2.5 mL of listerial supernatant and 2.5 mL of fresh medium (BHI for *Bs*, LB for *E. coli* and PYG modified for *Pc*). At 16 h after inoculation (in aerobic conditions for *Bs* and *E. coli* and in anaerobic conditions for *Pc*), cultures were serially diluted and plated on medium.

For *in vitro* assays, a peptide of 63aa (GTFWVTWGQDRHYSNYQHTKKTHRSSASNYRATERSSWKAKNNLATAWIKSSLWGNKANWATK), corresponding to the putative mature form of Lmo2776 has been chemically synthesized (Polypeptide) and diluted. 10^7^ bacteria were inoculated in absence or in presence of different concentrations of this peptide at 37°C into 5 mL of medium. At 16 h after inoculation (in aerobic or anaerobic conditions), cultures were serially diluted and plated.

For *in vivo* assays, conventional mice were anaesthetized with an intraperitoneal injection of 75 mg ketamine kg^−1^ and 5 mg xylazine kg^−1^. One hundred ul of Lmo2776 peptide (1mg in 100μl distilled H~2~O) was introduced rectally using a flexible catheter into each of 12 test mice and 100μl distilled H~2~O was introduced into each of 6 control mice. Feces were collected between 1 and 4 h following the introduction. Bacteria were quantified as described above.

### Immunostaining of Mucins and Localization of Bacteria by FISH {#sec4.4.7}

Colonic mucus immunostaining was paired with fluorescent *in situ* hybridization (FISH), as previously described ([@bib17], [@bib37]). Briefly, colonic tissues (proximal colon, 2nd cm from the cecum) containing fecal material were placed in methanol-Carnoy's fixative solution (60% methanol, 30% chloroform, 10% glacial acetic acid) for a minimum of 3 h at room temperature. Tissues were then washed in methanol 2 × 30 min, ethanol 2 × 15 min, ethanol/xylene (1:1) 15 min and xylene 2 × 15 min, followed by embedding in Paraffin with a vertical orientation. Five μm sections were performed and dewax by preheating at 60°C for 10 min, followed by xylene 60°C for 10 min, xylene for 10 min and 99.5% ethanol for 10 min. Hybridization step was performed at 50°C overnight with EUB338 probe (5′-GCTGCCTCCCGTAGGAGT-3′, with a 5′ labeling using Alexa 647) diluted to a final concentration of 10 μg/mL in hybridization buffer (20 mM Tris--HCl, pH 7.4, 0.9 M NaCl, 0.1% SDS, 20% formamide). After washing 10 min in wash buffer (20 mM Tris--HCl, pH 7.4, 0.9 M NaCl) and 3 × 10 min in PBS, PAP pen (Sigma-Aldrich) was used to mark around the section and block solution (5% fetal bovine serum in PBS) was added for 30 min at 4°C. Mucin-2 primary antibody (rabbit H-300, Santa Cruz Biotechnology, Dallas, TX, USA) was diluted 1:1500 in block solution and apply overnight at 4°C. After washing 3 × 10 min in PBS, block solution containing anti-rabbit Alexa 488 secondary antibody diluted 1:1500, Phalloidin-Tetramethylrhodamine B isothiocyanate (Sigma-Aldrich) at 1 μg/mL and Hoechst 33258 (Sigma-Aldrich) at 10 μg/mL was applied to the section for 2 h. After washing 3 × 10 min in PBS slides were mounted using Prolong anti-fade mounting media (Life Technologies, Carlsbad, CA, USA). Observations were performed with a Zeiss LSM 700 confocal microscope. The software Zen 2011 version 7.1 was used to measure the distance between bacteria and epithelial cell monolayer.

### Quantification of Fecal Lcn-2 by ELISA {#sec4.4.8}

Fecal samples were weighted, reconstituted in PBS-0.1% Tween 20 to a final concentration of 100 mg/mL and homogenized. Samples were then centrifuged for 10 min at 14 000 g and 4°C and supernatants were collected and stored at −20°C until analysis. Lcn-2 levels were measured using DuoSet mouse Lipocalin-2/NGAL ELISA kit (R&D Systems).

### Core genome MLST {#sec4.4.9}

*lmo2774*, *lmo2775*, *lmo2776* genes were screened in a collection of 1,696 publicly available genomes ([@bib54])representative of the diversity of lineages and sublineages of *Lm*. Genes were detected using the BLASTn algorithm implemented in BIGSdb-Lm platform v.1.17 (https://bigsdb.pasteur.fr/listeria; ([@bib39], [@bib54]), with minimum nucleotide identity of 70%, alignment length coverage of 70% and word size of 10.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Statistical Analysis {#sec4.5.1}

Statistically significant differences were evaluated by Mann--Whitney test, one way-ANOVA test or two-tailed unpaired Student's t test using Excel or Prism software. Statistical details of experiments and statistical tests are reported and described in the figure legends. Differences denoted in the text as significant fall below a p value of 0.05.

Data and Code Availability {#sec4.6}
--------------------------

### 16S rRNA Gene Sequence Analysis {#sec4.6.1}

Analysis of the 16S rRNA gene sequence was performed exactly as previously described ([@bib16]). Our full 16S rRNA gene sequence data are deposited under Study ID PRJEB34638 in the European Nucleotide Archive database (<https://www.ebi.ac.uk/ena>).
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